expand
use
molecular
assay
viral
pathogen
increasingli
recogn
among
critic
ill
adult
patient
communityacquir
sever
respiratori
ill
studi
detect
respiratori
viral
infect
rvi
patient
addit
novel
pathogen
includ
zoonot
coronavirus
like
agent
caus
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
novel
coronaviru
ncov
still
identifi
patient
sever
rvi
requir
icu
care
present
typic
hypoxem
respiratori
failur
oseltamivir
wide
use
neuraminidas
inhibitor
treatment
influenza
data
suggest
earli
use
associ
reduc
mortal
critic
ill
patient
influenza
present
antivir
therapi
proven
efficaci
sever
rvi
sever
adjunct
pharmacolog
intervent
studi
immunomodulatori
effect
includ
macrolid
corticosteroid
inhibitor
sirolimu
statin
antiinfluenza
immun
plasma
vitamin
c
none
recommend
present
sever
rvi
evidencebas
support
care
mainstay
manag
sever
respiratori
viral
infect
noninvas
ventil
patient
sever
rvi
caus
acut
hypoxem
respiratori
failur
pneumonia
associ
high
likelihood
transit
invas
ventil
limit
exist
knowledg
highlight
need
data
regard
support
care
adjunct
pharmacolog
therapi
specif
critic
ill
patient
sever
rvi
need
pragmat
effici
design
test
differ
therapeut
individu
combin
expand
use
molecular
assay
viral
pathogen
increasingli
detect
among
critic
ill
adult
patient
respiratori
ill
studi
report
preval
patient
tabl
depend
studi
design
sampl
type
durat
ill
assay
method
common
virus
caus
sever
respiratori
viral
infect
rvi
includ
influenza
b
virus
picornavirus
rhinoviru
enteroviru
eg
enteroviru
human
coronavirus
respiratori
syncyti
viru
rsv
human
metapneumoviru
parainfluenza
viru
adenoviru
tabl
novel
pathogen
includ
zoonot
coronavirus
like
agent
caus
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
novel
coronaviru
ncov
still
identifi
tabl
establish
causat
virus
detect
respiratori
specimen
clinic
ill
sometim
difficult
detect
agent
eg
picornavirus
upper
respiratori
tract
may
indic
asymptomat
mild
infect
upper
respiratori
tract
sampl
may
neg
despit
posit
lower
respiratori
tract
one
secondari
bacteri
less
often
fungal
infect
commonli
coidentifi
howev
gener
believ
respiratori
virus
caus
sever
ill
especi
elderli
person
comorbid
particularli
immunosuppress
occasion
previous
healthi
person
addit
predispos
secondari
infect
object
narr
review
outlin
current
knowledg
manag
adult
requir
icu
admiss
communityacquir
sever
acut
respiratori
infect
sari
due
rvi
review
focus
viral
pathogen
transmit
via
respiratori
rout
respiratori
infect
viral
pathogen
cytomegaloviru
herp
simplex
virus
discuss
review
gener
avail
antivir
agent
differ
rvi
summar
tabl
randomizedcontrol
trial
complet
patient
hospit
sever
rvi
recent
complet
trial
nitazoxanid
sari
patient
rsv
inhibitor
presatovir
adult
rsv
patient
yield
neg
result
antivir
therapeut
influenza
studi
extens
discuss
briefli
number
antivir
agent
influenza
rsv
rvi
advanc
clinic
studi
control
studi
lopinavirritonavir
combin
interferonbeta
hospitl
mer
patient
lopinavirritonavir
interferonalpha
hospit
patient
current
progess
among
neuraminidas
inhibitor
nai
oral
oseltamivir
wide
avail
agent
individu
particip
data
metaanalysi
hospit
patient
influenza
viru
infect
n
patient
studi
nai
treatment
almost
exclus
oseltamivir
associ
reduct
mortal
compar
treatment
includ
subgroup
icu
patient
earli
treatment
within
day
symptom
onset
associ
reduct
mortal
compar
later
treatment
observ
data
also
indic
reduct
influenza
associ
mortal
time
oseltamivir
treatment
onset
respiratori
failur
import
time
oseltamivir
treatment
demonstr
observ
studi
patient
admit
icu
influenza
show
trend
toward
improv
surviv
treat
earliest
nevertheless
clinic
practic
guidelin
infecti
diseas
societi
america
idsa
recommend
oseltamivir
hospit
patient
influenza
regardless
ill
durat
prior
hospit
observ
studi
critic
ill
patient
influenza
higher
compar
standard
dose
oseltamivir
demonstr
benefit
rct
standard
versu
doubledos
oseltamivir
hospit
children
adult
found
advantag
respect
virolog
clinic
endpoint
addit
studi
demonstr
accumul
oseltamivir
patient
extracorpor
membran
oxygen
continu
venoven
hemodiafiltr
lead
increas
plasma
level
idsa
recommend
routin
use
higher
dose
us
food
drug
administrationapprov
nai
drug
treatment
season
influenza
durat
treatment
tradit
day
treatment
durat
often
extend
day
sever
ill
patient
ard
pneumonia
immunocompromis
approach
support
data
show
slow
influenza
viral
clearanc
lower
respiratori
tract
critic
ill
patient
influenza
concern
recent
observ
emerg
oseltamivir
resist
critic
ill
patient
associ
persist
viru
detect
much
higher
mortal
nebul
zanamivir
solut
administ
mechan
ventil
patient
compassion
use
basi
commerci
formul
contain
lactos
use
nebul
use
associ
blockag
ventil
circuit
peramivir
intraven
influenza
antivir
agent
current
approv
us
food
drug
administr
fda
intraven
zanamivir
recent
approv
european
medicin
agenc
ema
tabl
agent
appear
compar
activ
oseltamivir
hospit
evidencebas
support
care
mainstay
manag
sever
respiratori
viral
infect
earli
treatment
neuraminidas
inhibitor
associ
reduc
mortal
sever
influenza
need
pragmat
effici
trial
design
test
varieti
investig
therapeut
individu
combin
influenza
patient
although
one
rct
compar
two
dose
level
intraven
zanamivir
oral
oseltamivir
found
trend
toward
shorter
ill
durat
subset
icu
patient
given
higher
dose
intraven
zanamivir
one
hand
one
rct
fail
demonstr
clinic
benefit
intraven
peramivir
hospit
patient
influenza
spectrum
activ
includ
oseltamivirresist
virus
intraven
zanamivir
indic
treatment
sever
influenza
b
patient
influenza
viru
known
suspect
resist
antiinfluenza
antivir
zanamivir
andor
antivir
includ
inhal
zanamivir
suitabl
tabl
two
phase
iii
trial
nonhospit
patient
influenza
found
singledos
baloxavir
superior
placebo
allevi
influenza
symptom
superior
oseltamivir
placebo
reduc
viral
replic
baloxavir
inhibitori
strain
resist
current
agent
howev
high
frequenc
emerg
variant
reduc
suscept
observ
monotherapi
doubleblind
rct
compar
oseltamivir
combin
oseltamivir
baloxavir
current
progress
hospit
patient
data
baloxavir
pharmacokinet
optim
dose
regimen
critic
influenza
ill
lead
icu
admiss
need
present
baloxavir
approv
us
japan
ten
countri
wide
varieti
agent
propos
manag
immunopatholog
host
respons
contribut
pathogenesi
sever
rvi
summar
progress
clinic
studi
includ
macrolid
corticosteroid
inhibitor
mtor
inhibitor
like
sirolimu
statin
highdos
vitamin
c
howev
evid
becom
avail
agent
use
manag
sever
rvi
unless
anoth
indic
part
clinic
trial
macrolid
antibiot
due
put
antiinflammatori
possibl
antivir
effect
studi
patient
rvi
inconsist
result
openlabel
rct
hospit
patient
influenza
n
earli
combin
therapi
clarithromycin
naproxen
oseltamivir
associ
reduc
mortal
hospit
length
stay
compar
oseltamivir
monotherapi
hand
multicent
observ
studi
n
macrolid
overal
preval
report
influenza
picornavirus
rhinoviru
enteroviru
human
coronavirus
respiratori
syncyti
viru
human
metapneumoviru
parainfluenza
viru
adenoviru
pleas
refer
onlin
supplement
refer
studi
vari
approach
sampl
use
assay
studi
specimen
collect
assay
standard
across
patient
studi
sampl
assay
perform
select
percentag
repres
patient
patient
one
viral
pathogen
isol
imv
invas
mechan
ventil
ta
tracheal
aspir
ifa
immunofluoresc
assay
naat
nucleic
acid
amplif
test
includ
commerci
inhous
pcr
rtpcr
pcr
multiplex
copd
chronic
obstruct
pulmonari
diseas
niv
noninvas
ventil
ps
nasopharyng
specimen
includ
nasopharyng
oropharyng
aspir
swab
bal
bronchoalveolar
lavag
cap
communityacquir
pneumonia
ili
influenzalik
ill
hcap
healthcareassoci
pneumonia
multipl
public
exist
cohort
includ
recent
one
supplementari
refer
associ
improv
surviv
critic
ill
patient
influenza
patient
mer
n
macrolid
therapi
associ
reduct
mortal
improv
merscov
rna
clearanc
studi
clarithromycin
combin
cyclooxygenas
inhibitor
flufenam
acid
hospit
patient
influenza
underway
addit
macrolid
also
examin
one
domain
remapcap
trial
random
embed
multifactori
adapt
platform
trial
communityacquir
pneumonia
data
use
corticosteroid
sever
rvi
larg
observ
sever
studi
demonstr
associ
corticosteroid
use
mortal
bacteri
fungal
infect
emerg
antivir
resist
influenzaassoci
pneumonia
ard
studi
n
account
timedepend
patientlevel
confound
found
independ
influenc
corticosteroid
mortal
influenza
idsa
recommend
corticosteroid
adjunct
therapi
patient
influenza
unless
clinic
indic
reason
studi
patient
hospit
rsv
n
corticosteroid
therapi
associ
signific
differ
peak
viral
load
durat
rsv
shed
nasal
cytokin
lymphocyt
subset
although
antibodi
respons
rsv
slightli
blunt
one
randomizedcontrol
trial
includ
nonicu
sar
patient
earli
day
ill
hydrocortison
therapi
associ
higher
subsequ
plasma
viral
load
studi
mer
patient
n
corticosteroid
therapi
associ
signific
chang
mortal
adjust
timevari
confound
associ
delay
merscov
rna
clearanc
may
modul
excess
proinflammatori
respons
sever
influenza
addit
studi
naproxenclarithromycin
ad
oseltamivir
preliminari
result
rct
n
show
combin
celecoxiboseltamivir
compar
oseltamivir
alon
reduc
mortal
cytokin
level
although
viral
titer
hospit
influenza
patient
without
increas
advers
effect
inhibitor
mtor
pathway
like
sirolimu
combin
oseltamivir
shown
inconsist
effect
murin
model
sever
influenza
sirolimu
also
modul
inflammatori
respons
immunosuppress
properti
small
rct
n
treatment
sirolimu
compar
sirolimu
patient
influenza
pneumonia
receiv
invas
mechan
ventil
addit
oseltamivir
corticosteroid
result
improv
hypoxia
multipl
organ
dysfunct
viru
clearanc
shorter
durat
mechan
ventil
studi
sirolimu
without
system
corticosteroid
plan
among
patient
hospit
influenza
put
antiinflammatori
effect
statin
propos
adjunct
therapi
influenza
although
larg
clinic
trial
patient
ard
demonstr
clinic
benefit
secondari
analysi
data
rct
use
latent
class
analysi
suggest
patient
ard
may
classifi
hyperinflammatori
hypoinflammatori
subphenotyp
treatment
simvastatin
compar
placebo
associ
improv
surviv
hyperinflammatori
hypoinflammatori
subphenotyp
studi
need
examin
whether
adjunct
pharmacolog
intervent
would
benefici
target
subphenotyp
sever
rvi
studi
variou
antibodi
immunotherapi
ad
neuraminidas
inhibitor
treatment
hospit
influenza
patient
yield
inconsist
result
small
randomizedcontrol
trial
n
demonstr
treatment
sever
influenza
patient
hyperimmun
globulin
hivig
contain
high
titer
virusspecif
neutral
antibodi
within
day
symptom
onset
associ
lower
viral
load
reduc
mortal
compar
lowtit
ivig
two
recent
phase
iii
trial
complet
season
influenza
patient
fluivig
rct
found
overal
effect
antiinfluenza
hyperimmun
ivig
compar
placebo
primari
outcom
measur
sixpoint
ordin
scale
clinic
statu
day
although
antivir
clinic
benefit
note
subgroup
patient
influenza
b
viru
infect
second
trial
hightit
versu
lowtit
antiinfluenza
immun
plasma
termin
futil
lack
effect
primari
outcom
placebocontrol
random
trial
antihemagglutinin
stem
monoclon
antibodi
demonstr
benefit
oseltamivir
alon
result
recent
trial
suggest
polyclon
antibodi
therapi
may
significantli
improv
outcom
sever
season
influenza
although
possibl
valu
treat
sever
rvi
novel
influenza
strain
remain
determin
recent
citrisali
trial
demonstr
infus
vitamin
c
compar
placebo
rel
small
number
n
patient
sepsi
ard
improv
primari
outcom
organ
dysfunct
score
alter
marker
inflamm
vascular
injuri
howev
mortal
one
fortysix
prespecifi
secondari
endpoint
significantli
lower
vitamin
c
result
ongo
larger
trial
await
data
sever
rvi
need
coinfect
bacteri
pathogen
occur
often
rvi
coinfect
staphylococcu
aureu
common
influenza
pneumonia
especi
virul
recent
atsidsa
clinic
practic
guidelin
recommend
standard
antibacteri
therapi
initi
prescrib
adult
communityacquir
pneumonia
test
posit
influenza
guidelin
provid
detail
consid
empir
therapi
methicillin
resist
staphylococcu
aureu
pseudomona
aeruginosa
provid
guidanc
deescal
antibacteri
therapi
patient
confirm
influenza
clinician
awar
report
invas
pulmonari
aspergillosi
sever
ill
influenza
patient
especi
underli
condit
receiv
corticosteroid
although
patient
influenzaassoci
aspergillosi
previous
healthi
patient
sever
rvi
present
typic
pneumonia
acut
respiratori
distress
syndrom
ard
decompens
heart
failur
exacerb
chronic
lung
diseas
lead
frequent
acut
hypoxem
less
commonli
hypercapn
respiratori
failur
except
sever
influenza
novel
coronaviru
studi
note
data
regard
support
care
strategi
come
studi
document
specif
rvi
mani
ard
trial
patient
pneumonia
constitut
major
enrol
patient
detail
descript
etiolog
pathogen
often
lack
given
high
preval
viral
pathogen
outlin
earlier
like
sever
rvi
constitut
consider
proport
gener
pathophysiolog
clinic
similar
ard
pneumonia
caus
sever
rvi
due
pathogen
etiolog
therefor
extrapol
find
unselect
popul
patient
sever
rvi
justifi
absenc
specif
data
time
import
differ
may
lead
heterogen
respons
treatment
data
noninvas
ventil
niv
sever
rvi
limit
patient
sever
rvi
result
chronic
obstruct
pulmonari
diseas
copd
exacerb
cardiogen
pulmonari
edema
niv
may
effect
reduc
need
endotrach
intub
decreas
ventilatorassoci
complic
mortal
howev
niv
patient
sever
rvi
caus
acut
hypoxem
respiratori
failur
pneumonia
uncertain
benefit
observ
studi
report
variabl
result
niv
patient
sever
influenza
report
niv
failur
one
multicent
observ
studi
critic
ill
patient
acut
hypoxem
respiratori
failur
due
influenza
underw
initi
niv
requir
convers
invas
ventil
patient
sofa
higher
risk
niv
failur
similar
studi
niv
failur
associ
increas
icu
mortal
compar
invas
mechan
ventil
data
uncontrol
studi
suggest
niv
might
effect
safe
manag
patient
sar
other
highlight
concern
increas
sar
transmiss
risk
healthcar
worker
multicent
cohort
mer
critic
ill
patient
niv
use
initi
patient
vast
major
requir
convers
invas
mechan
ventil
howev
niv
independ
associ
mortal
recent
singlecent
rct
patient
unselect
patient
ard
n
pneumonia
show
treatment
helmet
niv
result
signific
reduct
intub
rate
mortal
studi
patient
sever
rvi
need
helmet
niv
may
effect
tradit
mask
may
associ
less
risk
transmiss
due
aerosol
gener
base
avail
evid
niv
sever
rvi
may
use
select
patient
earli
stage
milder
form
acut
hypoxem
respiratori
failur
exclud
shock
multiorgan
failur
recognit
patient
show
sign
earli
recoveri
niv
may
well
delay
avoid
invas
ventil
highflow
nasal
cannula
emerg
altern
niv
prevent
intub
patient
acut
hypoxem
respiratori
failur
one
trial
n
communityacquir
pneumonia
treatment
highflow
oxygen
standard
oxygen
niv
result
significantli
differ
intub
rate
howev
signific
differ
favor
highflow
nasal
cannula
mortal
small
cohort
patient
sever
rvi
influenza
n
show
highflow
nasal
cannula
associ
avoid
intub
patient
although
almost
patient
higher
sever
ill
shock
eventu
intub
base
current
evid
patient
ard
due
sever
rvi
manag
lungprotect
strategi
low
tidal
volum
mlkg
predict
bodi
weight
plateau
pressur
cmh
adult
acut
lung
injuri
ard
due
variou
caus
individu
patient
data
metaanalysi
patient
three
trial
pneumonia
found
higher
posit
endexpiratori
pressur
peep
level
associ
improv
surviv
among
subgroup
patient
ard
defin
pao
fio
mmhg
recent
rct
patient
moderatetosever
ard
pneumonia
demonstr
prolong
highpressur
recruit
maneuv
associ
increas
mortal
titrat
peep
achiev
optim
oxygen
perhap
without
aggress
recruit
maneuv
remain
reason
strategi
patient
hfov
ventil
lung
tidal
volum
lower
anatom
dead
space
achiev
rel
high
mean
airway
pressur
patient
influenza
influenza
hfov
use
rescu
therapi
respond
convent
ventil
two
random
clinic
trial
show
hfov
moderatetosever
ard
associ
improv
outcom
compar
convent
ventil
howev
metaanalysi
patient
pneumonia
found
hfov
treatment
effect
depend
baselin
sever
hypoxemia
harm
among
patient
mildmoder
ard
possibl
decreas
mortal
patient
sever
ard
therefor
hfov
recommend
routin
use
ard
may
still
role
rescu
therapi
multicent
rct
n
pneumonia
demonstr
earli
applic
prone
posit
least
h
per
session
patient
sever
ard
pao
fio
mmhg
fio
peep
cmh
tidal
volum
close
mlkg
predict
bodi
weight
result
decreas
mortal
prone
posit
patient
avian
influenzarel
sever
ard
associ
improv
oxygen
sustain
return
supin
posit
decreas
carbon
dioxid
retent
patient
sever
ard
one
trial
n
communityacquir
pneumonia
earli
administr
neuromuscular
block
agent
improv
adjust
surviv
increas
time
ventil
without
increas
muscl
weak
howev
recent
larger
trial
enrol
patient
moderatetosever
ard
n
pneumonia
treat
strategi
involv
high
peep
signific
differ
mortal
day
patient
receiv
earli
continu
cisatracurium
infus
treat
usualcar
approach
lighter
sedat
target
specif
data
neuromuscular
blockad
sever
rvi
lack
latest
rct
ecmo
eolia
includ
patient
sever
ard
viral
etiolog
found
ecmo
reduc
mortal
day
yet
post
hoc
bayesian
analysi
found
interpret
benefit
versu
benefit
trial
critic
depend
upon
rang
prior
assumpt
reflect
vari
degre
skeptic
enthusiasm
previou
evid
benefit
ecmoclinician
enthusiasm
benefit
ecmo
may
justifi
consid
certain
patient
inde
observ
studi
report
lower
hospit
mortal
among
patient
ard
relat
influenza
transfer
ecmo
center
compar
match
nonecmoref
patient
casecontrol
studi
also
suggest
surviv
benefit
ecmo
patient
sever
mer
ecmo
like
associ
better
outcom
use
among
patient
limit
organ
failur
good
premorbid
function
statu
consid
patient
fail
evidencebas
oxygen
strategi
accord
individu
patient
characterist
potenti
riskbenefit
determin
time
adequ
fluid
resuscit
essenti
element
manag
patient
sever
rvi
shock
howev
ard
n
pneumonia
conserv
strategi
fluid
manag
improv
lung
function
shorten
durat
mechan
ventil
without
increas
nonpulmonaryorgan
failur
addit
aggress
fluid
administr
may
worsen
ventricular
function
may
particularli
relev
patient
sever
rvi
myocardi
involv
uncommon
sever
influenza
b
viru
infect
multipl
studi
shown
associ
influenza
acut
myocardi
infect
myocard
echocardiograph
find
often
includ
rightand
leftventricular
dysfunct
therefor
clinic
assess
fluid
respons
import
along
quantif
rightand
leftventricular
size
function
use
echocardiographi
andor
dynam
minim
invas
cardiovascular
monitor
avail
myocard
associ
longer
durat
vasoact
agent
mortal
may
sometim
requir
ecmo
type
support
care
tabl
footnot
cdc
refer
patient
present
sever
rvi
contact
plu
droplet
precaut
recommend
droplet
precaut
may
discontinu
adenoviru
influenza
rule
patient
histori
recent
travel
day
countri
activ
outbreak
sar
mer
avian
influenza
airborn
plu
contact
precaut
eye
protect
recommend
aerosolgener
procedur
bronchoscopi
endotrach
intub
open
suction
respiratori
tract
tracheotomi
manual
ventil
intub
nebul
treatment
highflow
nasal
cannula
noninvas
ventil
chest
compress
implic
transmiss
infecti
agent
healthcar
personnel
howev
find
identifi
limit
studi
mainli
sar
outbreak
nevertheless
recommend
aerosolgener
procedur
patient
suspect
proven
infect
transmit
aerosol
exampl
influenza
mer
sar
wear
fittest
mask
addit
glove
gown
faceey
protect
closedcircuit
suction
may
reduc
exposur
aerosol
perform
procedur
airborn
isol
room
feasibl
recommend
rct
compar
respir
medic
mask
health
care
personnel
work
outpati
ward
set
shown
signific
differ
protect
laboratoryconfirm
influenza
rvi
relev
observ
icu
set
uncertain
given
frequent
use
aerosolgener
procedur
critic
ill
patient
cloth
mask
clearli
inferior
medic
mask
protect
hcw
rvi
aspect
prevent
strategi
prevent
transmiss
care
patient
sever
rvi
includ
annual
influenza
vaccin
healthcar
worker
adher
standard
precaut
includ
hand
hygien
care
patient
appropri
manag
ill
healthcar
worker
pleas
refer
tabl
footnot
cdc
refer
recent
antisept
hand
rub
use
ethanolbas
disinfect
ebd
found
less
effect
hand
wash
run
water
inactiv
influenza
viru
undri
mucu
experiment
condit
also
nonenvelop
virus
like
adenoviru
easili
inactiv
ebd
implic
observ
clinic
practic
remain
determin
hand
wash
soap
water
hand
rub
ebd
longer
may
warrant
global
influenza
programm
publish
updat
public
health
research
agenda
influenza
research
prioriti
identifi
sever
domain
includ
patient
manag
exist
knowledg
highlight
need
data
regard
support
care
adjunct
pharmacolog
therapi
specif
critic
ill
patient
sever
rvi
data
support
manag
resourcerestrict
set
sever
lack
need
pragmat
effici
design
test
antivir
therapeut
individu
combin
patient
sever
rvi
increas
risk
complic
diseas
treatment
adapt
randomizedcontrol
trial
test
sever
treatment
remapcap
trial
may
repres
effici
approach
onlin
version
articl
http
contain
supplementari
materi
avail
author
user
